KR102626748B1 - 임상용 변형된 NK-92 haNK003 세포 - Google Patents

임상용 변형된 NK-92 haNK003 세포 Download PDF

Info

Publication number
KR102626748B1
KR102626748B1 KR1020237015931A KR20237015931A KR102626748B1 KR 102626748 B1 KR102626748 B1 KR 102626748B1 KR 1020237015931 A KR1020237015931 A KR 1020237015931A KR 20237015931 A KR20237015931 A KR 20237015931A KR 102626748 B1 KR102626748 B1 KR 102626748B1
Authority
KR
South Korea
Prior art keywords
cells
hank003
pharmaceutical composition
cell
irradiated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237015931A
Other languages
English (en)
Korean (ko)
Other versions
KR20230074281A (ko
Inventor
한스 클링게만
로렌스 보이셀
패트릭 순-시옹
Original Assignee
이뮤너티바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤너티바이오, 인크. filed Critical 이뮤너티바이오, 인크.
Priority to KR1020247001475A priority Critical patent/KR102769529B1/ko
Publication of KR20230074281A publication Critical patent/KR20230074281A/ko
Application granted granted Critical
Publication of KR102626748B1 publication Critical patent/KR102626748B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237015931A 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포 Active KR102626748B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247001475A KR102769529B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762468890P 2017-03-08 2017-03-08
US62/468,890 2017-03-08
PCT/US2018/021332 WO2018165291A1 (en) 2017-03-08 2018-03-07 MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
KR1020197028804A KR102533061B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028804A Division KR102533061B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001475A Division KR102769529B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Publications (2)

Publication Number Publication Date
KR20230074281A KR20230074281A (ko) 2023-05-26
KR102626748B1 true KR102626748B1 (ko) 2024-01-17

Family

ID=63446373

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020237015931A Active KR102626748B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020247001475A Active KR102769529B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020257004694A Pending KR20250026391A (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020197028804A Active KR102533061B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247001475A Active KR102769529B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020257004694A Pending KR20250026391A (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020197028804A Active KR102533061B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Country Status (9)

Country Link
US (5) US10801013B2 (https=)
EP (1) EP3592845A4 (https=)
JP (5) JP7098648B2 (https=)
KR (4) KR102626748B1 (https=)
CN (2) CN116440293A (https=)
AU (2) AU2018231193B2 (https=)
CA (1) CA3053252C (https=)
IL (3) IL326426A (https=)
WO (1) WO2018165291A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10801013B2 (en) 2017-03-08 2020-10-13 Nantkwest, Inc. Modified NK-92 haNK003 cells for the clinic
JP7241161B2 (ja) 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
EP3743512A4 (en) 2018-10-31 2021-12-01 Nantkwest, Inc. ELIMINATION OF CD19 POSITIVE LYMPHOID MALIGNITIES BY CD19 CAR EXPRESSING NK CELLS
CN113164521A (zh) * 2018-11-26 2021-07-23 免疫生物公司 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
EP3938495A4 (en) 2019-03-15 2023-04-26 Nantcell, Inc. RECOMBINANT ERIL-15 NK CELLS
CA3148608A1 (en) * 2019-07-26 2021-02-04 Immunitybio, Inc. Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
AU2020387167B2 (en) * 2019-11-20 2024-10-24 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
CN113646435A (zh) * 2019-12-09 2021-11-12 南克维斯特公司 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
EP4232567A1 (en) * 2020-10-26 2023-08-30 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用
EP4548096A1 (en) * 2022-06-28 2025-05-07 Cellply S.R.L. Method for the characterization of products for cell therapy
US20250298030A1 (en) * 2024-03-20 2025-09-25 Immunitybio, Inc. Compositions and Methods for NK-92 Cells Expressing Native CD16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510698A (ja) * 1995-08-04 1999-09-21 ザ ジェネラル ホスピタル コーポレイション トランスジェニックブタ及びヒトｈｌａ遺伝子を有するブタ細胞
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
CA2289915A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
ATE323756T1 (de) 1997-04-30 2006-05-15 Hans Klingemann Natürliche killerzelllinien und verfahren zu ihrer verwendung
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
AU2005277831B2 (en) * 2004-07-10 2012-11-22 The Institute For Cancer Research Genetically modified human natural killer cell lines
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
CN117379460A (zh) * 2015-03-27 2024-01-12 免疫生物公司 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体
EP3307876B1 (en) 2015-06-10 2023-09-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
US10801013B2 (en) 2017-03-08 2020-10-13 Nantkwest, Inc. Modified NK-92 haNK003 cells for the clinic

Also Published As

Publication number Publication date
US20200347351A1 (en) 2020-11-05
AU2018231193A1 (en) 2019-08-08
CN110418839A (zh) 2019-11-05
CN110418839B (zh) 2023-06-09
JP2022130596A (ja) 2022-09-06
EP3592845A1 (en) 2020-01-15
IL268617B2 (en) 2025-03-01
JP2020511131A (ja) 2020-04-16
CN116440293A (zh) 2023-07-18
US20260078342A1 (en) 2026-03-19
KR102769529B1 (ko) 2025-02-19
EP3592845A4 (en) 2020-12-30
KR20230074281A (ko) 2023-05-26
JP7806197B2 (ja) 2026-01-26
US20240010979A1 (en) 2024-01-11
KR20240010558A (ko) 2024-01-23
JP7608580B2 (ja) 2025-01-06
US11753625B2 (en) 2023-09-12
US20180258397A1 (en) 2018-09-13
AU2021236511A1 (en) 2021-10-28
KR20190118204A (ko) 2019-10-17
AU2018231193B2 (en) 2021-07-22
JP2025038128A (ja) 2025-03-18
WO2018165291A1 (en) 2018-09-13
CA3053252C (en) 2023-02-21
JP2026063125A (ja) 2026-04-10
IL316209A (en) 2024-12-01
KR20250026391A (ko) 2025-02-25
IL326426A (en) 2026-04-01
AU2021236511B2 (en) 2021-12-16
US12492377B2 (en) 2025-12-09
CA3053252A1 (en) 2018-09-13
US10801013B2 (en) 2020-10-13
JP7098648B2 (ja) 2022-07-11
IL316209B1 (en) 2026-03-01
US10774310B2 (en) 2020-09-15
KR102533061B1 (ko) 2023-05-15
JP7398518B2 (ja) 2023-12-14
US20190300854A1 (en) 2019-10-03
IL268617B1 (en) 2024-11-01
JP2024023513A (ja) 2024-02-21
IL268617A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7608580B2 (ja) 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
KR102096592B1 (ko) 신규한 crispr 연관 단백질 및 이의 용도
AU2023202642B2 (en) IL-2 Dependent NK-92 cells with stable Fc receptor expression
US20250354978A1 (en) Method to assess potency of viral vector particles
CA3135166A1 (en) Compositions and methods for retrieving tumor-related antibodies and antigens
CN111450098A (zh) 拉米夫定在延缓衰老中的应用以及制备用于筛选延缓衰老药物的细胞模型
CN114616239B (zh) 嵌合抗原受体和其中表达有嵌合抗原受体的t细胞
CN107058390A (zh) 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
CN113710268B (zh) 药物递送组合物
CN121565247A (zh) 一种基于tbr1定点突变体的抗肿瘤药物细胞筛选模型建立方法及应用

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230511

Application number text: 1020197028804

Filing date: 20191001

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230620

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231025

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240115

Application number text: 1020197028804

Filing date: 20191001

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration